Results follow recent updates to ProMIS
antibody programs selectively targeting root cause of multiple
neurodegenerative diseases
TORONTO and CAMBRIDGE, MA, Oct. 23,
2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX:
PMN) (OTCQB: ARFXF), a biotechnology company focused on the
discovery and development of antibody therapeutics targeting toxic
oligomers implicated in the development of neurodegenerative
diseases, has generated antibody candidates targeting the
neurotoxic form of TAR DNA-binding protein 43 (TDP-43), a protein
found in all cells and implicated as a root cause in a spectrum of
diseases such as amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD).
New data generated by ProMIS' unique drug discovery and
development platform demonstrate that several antibody candidates
show selectivity for toxic, misfolded intracellular aggregates of
TDP-43 with no binding to normal TDP-43 located in the cell
nucleus. ProMIS antibody candidates also show selective binding to
the pathogenic, misfolded form of TDP-43 in post-mortem brain
tissue from patients with FTD.
"The momentum behind each of our programs is palpable," said
Elliot Goldstein, MD, ProMIS
Neurosciences President and CEO. "In the past 30 days, we've
announced data advancing our development programs selectively
targeting toxic misfolded proteins for treatment of Alzheimer's and
Parkinson's disease and Multiple System Atrophy (MSA), ALS and FTD.
Yesterday, Biogen's decision to submit its amyloid-beta targeting
drug candidate, aducanumab, for FDA approval signaled a milestone
shift in the promise of next-generation amyloid-beta targeting
drugs. Our lead program, PMN310, offers sniper-like precision for
the toxic, misfolded form of amyloid beta, a key feature that
offers important potential advantages compared to aducanumab. We
will continue to support the patient community by advancing our
programs, in particular PMN310 for Alzheimer's disease, leveraging
our proprietary, drug discovery platform."
To learn more about the search for therapies for Alzheimer's,
Parkinson's and other neurodegenerative diseases, listen to the
podcast, Saving Minds, at iTunes or Spotify.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc.
is a development stage biotechnology company focused on discovering
and developing antibody therapeutics selectively targeting toxic
oligomers implicated in the development and progression of
neurodegenerative diseases, in particular Alzheimer's disease (AD),
amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).
The Company's proprietary target discovery platform is based on the
use of two complementary thermodynamic, computational discovery
engines – ProMIS and Collective Coordinates – to predict novel
targets known as Disease Specific Epitopes on the molecular surface
of misfolded proteins. Using this unique precision approach, the
Company is developing novel antibody therapeutics for AD, ALS and
PD. ProMIS is headquartered in Toronto,
Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on
the Toronto Stock Exchange under the symbol PMN, and on the OTCQB
Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com, follow us
on Twitter and LinkedIn
The TSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This information
release contains certain forward-looking information. Such
information involves known and unknown risks, uncertainties and
other factors that may cause actual results, performance or
achievements to be materially different from those implied by
statements herein, and therefore these statements should not be
read as guarantees of future performance or results. All
forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently
available to it as well as other factors. Readers are cautioned not
to place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
the Company in its public securities filings, actual events may
differ materially from current expectations. The Company disclaims
any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/promis-neurosciences-advances-als-program-selectively-targeting-toxic-form-of-tdp-43-300943976.html
SOURCE ProMIS Neurosciences Inc.